Epidyolex, a cannabidiol-based medicinal cannabis product, has established a robust reputation as the premier player in the realm of pharmaceutical therapies available on Australia’s Pharmaceutical Benefits Scheme (PBS). This groundbreaking product is now accessible as a treatment option for Dravet syndrome, a rare and debilitating genetic epileptic encephalopathy. This cruel condition takes root in the first year of life, sneaking up on otherwise healthy infants to trigger seizures that are notoriously unresponsive to conventional medications. The inclusion of Epidyolex on the PBS is a welcome relief for the multitude of families affected by this disorder. Its listing on the PBS is the result of extensive research and trials that have conclusively proven its effectiveness in reducing both the frequency and intensity of seizures in children afflicted with Dravet syndrome. This significant step forward marks a pivotal advancement for Australian families who have been grappling with the distressing effects of this disorder on their loved ones. Epidyolex’s reputation as an efficient and well-tolerated medication is further bolstered by its minimal side effects. The majority of patients respond well to the drug, experiencing little to no side effects. This contributes to its status as a preferred treatment option, particularly when compared to other anti-epileptic drugs that may have more substantial side effects. However, beyond its medical benefits, the enhanced affordability of Epidyolex represents a significant progression in the accessibility of crucial treatments. Prior to its inclusion on the PBS, Epidyolex, like many other medicinal cannabis products, was prohibitively expensive for many families. However, with its PBS listing, the medication is now financially accessible to a larger demographic, opening the doors to a new realm of treatment possibility for patients suffering from Dravet syndrome. It is noteworthy that numerous other medicinal cannabis products available in Australia remain unlisted on the PBS and thus, are expensive to access. These potential life-altering drugs are not within the reach of many who could benefit from them, presenting a significant barrier to treatment. However, there is a glimmer of hope on the horizon. The Australian government has launched an ongoing review of the PBS listing process for medicinal cannabis products. This review promises potential expansion in the future, with the potential to unleash a slew of affordable, effective treatments for a range of disorders. This progressive action by the government is a promising sign of the increasing recognition of the therapeutic potential of cannabis-derived medicines. In conclusion, the inclusion of Epidyolex on the PBS is a significant step forward in the treatment of Dravet syndrome in Australia. It offers a beacon of hope for affected families, offering an effective and affordable treatment option where few existed before. More broadly, the ongoing review of the PBS listing process for medicinal cannabis products signals a potentially transformative shift in the landscape of medical treatments in Australia.